improves patient outcomes vs standard of care: Results of a prospective randomized controlled multi-center clinical trial
The prevalence of diabetes in the United States continues to rise, with the disease now affecting 34.2 million, with an estimated additional 84 million at risk of progressing to diabetes in the coming years.1 The lifetime incidence of DFUs among diabetics is 19% to 34%, with recurrent ulceration reported as approximately 40% at 1 year and 60% at 3 years.2 Management is challenging and associated with substantial socio-economic burden approaching $40 billion annually in direct costs.3 Approximately 70% of DFUs resolve with standard wound care therapies. However, the natural healing cascade is arrested in the remaining 30%, which ultimately become chronic wounds.4, 5 Patients with chronic wounds typically suffer loss of function, recurrent infection, and significant morbidity.6 Amputations are reported in up to 20% of cases with an associated mortality of 70% at 5 years post-amputation … read more